Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid - short RadioTherapy - rectum 3rd trial)Antonio Avallone, Alfredo Budillon, Maria Carmela Piccirillo et al.|BMC Cancer|2014Cited by 41
2006 A phase III multicenter trial comparing two different sequences of second/third line therapy (cetuximab/irinotecan followed by FOLFOX versus FOLFOX followed by cetuximab/irinotecan) in metastatic K-RAS wt colorectal cancer (mCC) patients, refractory to FOLFIRI/Bevacizumab)Stefano Cascinu, Irene Floriani, Massimo Aglietta et al.|European Journal of Cancer|2015Cited by 5
A phase III multicenter trial comparing two different sequences of second/third line therapy (irinotecan/cetuximab followed by FOLFOX-4 vs. FOLFOX-4 followed by irinotecan/cetuximab in K-RAS wt metastatic colorectal cancer (mCC) patients refractory to FOLFIRI/BevacizumabGerardo Rosati, Stefano Cascinu, Guglielmo Nasti et al.|Annals of Oncology|2015Cited by 2